Stories

The first six months of 2025 have been exceptional for Ipsen. We’ve delivered strong growth across all three of our therapeutic areas — Rare Disease, Oncology, and Neuroscience — reflecting the strength of our strategy and the dedication of our teams. 

Every person’s experience living with neuroendocrine tumors (NETs) is unique and for Melanie, coming to terms with a diagnosis of lung NETs is an ongoing journey, building knowledge and understanding of how to live with this complex and often unknown form of cancer.

Ipsen’s financial results for the first nine months of 2025 were published on 22 October 2025.

Hugo Gomes da Silva, SVP Global Medical Affairs (Rare Disease) at Ipsen, shares powerful insights into the evolving challenges families face throughout their PFIC journey—and highlights the critical importance of trusted information and community support.  

Nathan McCormack focuses on the earliest stages of active pharmaceutical ingredient (API) development.